Redeye comments on Evolution’s Q4-results which were in line with our forecasts.
Sales -3%, adj. EBITA -8% vs. cons, -6% org. growth Consensus to lower '24e-'25e EBITA by 3-5% Share...
We lower adjusted EBITA by 5% for 2025E-27E following the Q4 report.
Redeye comments on Embracer’s preliminary Q3-results which came in stronger than expected, driven ma...
Redeye is encouraged by the recent news regarding Integrum’s increased educational activities, toget...
Redeye provides a preview of SSH's Q4 results set to be released on February 14.
On January 29th, Eevia Health Plc (publ) (“Eevia”) announced ten new sales orders for products total...
Taaleri Real Estate and Keva (Finland’s largest pension insurer, responsible for providing pensions ...
Cost-effective coatings for hydrogen and metallisation applications Seizing opportunities in Chinese...
XVIVO Q4 is another solid quarter with 44% organic growth (CER), 6-7% above expectations.
Q4 not likely to be a game-changer New design win with Dell opens large new segment Ambition of 50-6...
Q4'24e organic sales growth of 24% y-o-y Minor estimate changes FVR of SEK 30-45 reiterated What to...
Redeye comments on the outcome of Ngenic’s rights issue, which was subscribed to 88%, injecting Ngen...
Redeye provides a preview of CoinShares and updates its estimates ahead of the Q4 2024 report expect...
Redeye provides a brief comment on the final rights issue terms announced yesterday.
In Q4-24, Eevia Health Plc (publ) (“Eevia” or “the Company”) launched a transformational restructuri...
SEK 120+7m retrofit order to be delivered in 2025-2035 Covers our '25e-'28e Retrofit assumptions, ~1...
Ramlösa Shipping (”Ramlösa” eller ”Bolaget”) meddelade den 27 januari att bolaget blir delägare i Ca...
Redeye gives its preview on OssDsign’s Q3 2024 report, due on February 4.
Redeye comments on Heliospectra’s proposed rights issue, fully secured by its main owner, Weland Stå...
